# Metabolic Plasticity in Schizophrenia: Clinical Rehabilitation Meets LC–MS Metabolomics and Neurofeedback

**Authors:** Mateusz Trubalski, Renata Markiewicz, Agnieszka Markiewicz-Gospodarek, Grzegorz Kalisz, Bartosz Łoza, Sylwia Szymańczyk

PMC · DOI: 10.3390/ijms27010380 · International Journal of Molecular Sciences · 2025-12-29

## TL;DR

This study explores how metabolic changes in schizophrenia are affected by different non-invasive therapies and standard drug treatments.

## Contribution

The study characterizes metabolic changes in schizophrenia patients using non-invasive therapies and compares them to standard pharmacotherapy.

## Key findings

- Schizophrenia is linked to systemic metabolic disturbances in energy, amino acid, lipid, and redox pathways.
- Antipsychotic treatment alters a wide range of metabolites, complicating biomarker discovery.
- No single biomarker has achieved clinical utility, but validated panels show potential causal links to schizophrenia risk.

## Abstract

Metabolomics research in schizophrenia has revealed consistent alterations across multiple biochemical domains, including energy metabolism, lipid composition, amino acid pathways, and oxidative stress regulation. The most reproducible findings include the dysregulation of the tryptophan–kynurenine pathway, disturbances in arginine/nitric oxide metabolism, alterations in phospholipid and sphingolipid profiles, reduced glutathione (GSH) in the brain, and elevated lactate levels, suggesting mitochondrial dysfunction. Antipsychotic treatment itself modifies a wide range of metabolites, complicating biomarker discovery. Although no single biomarker has yet achieved clinical utility, systematic reviews and Mendelian randomization studies provide evidence for validated biomarker panels and potential causal links between peripheral metabolite signatures and schizophrenia risk. The aim of this study is to characterize metabolic changes in patients diagnosed with schizophrenia, where each group received different non-invasive therapeutic methods and was compared to patients continuing standard pharmacotherapy without modification. The study results show that schizophrenia is associated with systemic metabolic disturbances affecting energy, amino acid, lipid, and redox pathways. Further development of research in this area requires comprehensive and long-term studies integrated with modern imaging and analytical techniques.

## Linked entities

- **Chemicals:** glutathione (GSH) (PubChem CID 124886), lactate (PubChem CID 61503)
- **Diseases:** schizophrenia (MONDO:0005090)

## Full-text entities

- **Diseases:** Metabolic (MESH:D008659), mitochondrial dysfunction (MESH:D028361), Schizophrenia (MESH:D012559)
- **Chemicals:** lactate (MESH:D019344), tryptophan (MESH:D014364), nitric oxide (MESH:D009569), phospholipid (MESH:D010743), kynurenine (MESH:D007737), lipid (MESH:D008055), arginine (MESH:D001120), GSH (MESH:D005978), sphingolipid (MESH:D013107), amino acid (MESH:D000596)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12785504/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12785504/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC12785504/full.md

---
Source: https://tomesphere.com/paper/PMC12785504